DOCSLIB.ORG

Identification of 5 Novel Genes Methylated in Breast and Other Epithelial Cancers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of 5 Novel Genes Methylated in Breast and Other Epithelial Cancers Identification of 5 novel genes methylated in breast and other epithelial cancers. Victoria Hill, Luke Hesson, Temuujin Dansranjavin, Ashraf Dallol, Ivan Bieche, Sophie Vacher, Stella Tommasi, Timothy Dobbins, Dean Gentle, David Euhus, et al. To cite this version: Victoria Hill, Luke Hesson, Temuujin Dansranjavin, Ashraf Dallol, Ivan Bieche, et al.. Identification of 5 novel genes methylated in breast and other epithelial cancers.. Molecular Cancer, BioMed Central, 2010, 9 (1), pp.51. 10.1186/1476-4598-9-51. inserm-00663769 HAL Id: inserm-00663769 https://www.hal.inserm.fr/inserm-00663769 Submitted on 27 Jan 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Hill et al. Molecular Cancer 2010, 9:51 http://www.molecular-cancer.com/content/9/1/51 RESEARCH Open Access Identification of 5 novel genes methylated in breast and other epithelial cancers Victoria K Hill1, Luke B Hesson1,2, Temuujin Dansranjavin3, Ashraf Dallol1, Ivan Bieche4, Sophie Vacher4, Stella Tommasi5, Timothy Dobbins2, Dean Gentle1, David Euhus6, Cheryl Lewis6, Reinhard Dammann3, Robyn L Ward2, John Minna7, Eammon R Maher1, Gerd P Pfeifer5, Farida Latif1* Abstract Background: There are several high throughput approaches to identify methylated genes in cancer. We utilized one such recently developed approach, MIRA (methylated-CpG island recovery assay) combined with CpG island arrays to identify novel genes that are epigenetically inactivated in breast cancer. Results: Using this approach we identified numerous CpG islands that demonstrated aberrant DNA methylation in breast cancer cell lines. Using a combination of COBRA and sequencing of bisulphite modified DNA, we confirmed 5 novel genes frequently methylated in breast tumours; EMILIN2, SALL1, DBC1, FBLN2 and CIDE-A. Methylation frequencies ranged from between 25% and 63% in primary breast tumours, whilst matched normal breast tissue DNA was either unmethylated or demonstrated a much lower frequency of methylation compared to malignant breast tissue DNA. Furthermore expression of the above 5 genes was shown to be restored following treatment with a demethylating agent in methylated breast cancer cell lines. We have expanded this analysis across three other common epithelial cancers (lung, colorectal, prostate). We demonstrate that the above genes show varying levels of methylation in these cancers. Lastly and most importantly methylation of EMILIN2 was associated with poorer clinical outcome in breast cancer and was strongly associated with estrogen receptor as well as progesterone receptor positive breast cancers. Conclusion: The combination of the MIRA assay with CpG island arrays is a very useful technique for identifying epigenetically inactivated genes in cancer genomes and can provide molecular markers for early cancer diagnosis, prognosis and epigenetic therapy. Background Genetic as well as epigenetic changes play crucial roles In most Western countries breast cancer is a leading in tumour development and progression. Alterations in cause of cancer related deaths in women. Breast cancer DNA methylation include both genome-wide hypo- accounts for over one million of the estimated 10 million methylation and hypermethylation events. Promoter cancers that are diagnosed globally each year in both hypermethylation at specific gene loci is a major mechan- males and females and claimed about 375,000 deaths in ism of epigenetic inactivation in cancer cells leading to the year 2000 [1]. The use of screening mammography gene silencing. A recent genome-wide study in breast and MRI has led to a decline in breast cancer-related and colon cancer led to identification of tumour suppres- mortality. But these screening procedures can also lead sor genes that are inactivated by both genetic and epige- to overdiagnosis and false positive cases leading to unne- netic events and importantly reduced expression of a cessary treatment. Therefore there is a critical need to subset of these genes correlated with poor clinical out- develop molecular biomarkers that can detect early stage come [2]. Although the list of hypermethylated genes in disease so that treatment can begin promptly. breast cancer is growing, only a few show promise as bio- markers for early detection and risk assessment [3,4]. We * Correspondence: [email protected] and others identified RASSF1A as one of the most highly 1 Department of Medical and Molecular Genetics, School of Clinical and methylated genes in many cancer types including breast Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK cancer [5,6]. Identification of more genes of this type © 2010 Hill et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hill et al. Molecular Cancer 2010, 9:51 Page 2 of 13 http://www.molecular-cancer.com/content/9/1/51 would facilitate the development of sensitive molecular Methylation analysis in breast tumours and breast markers across multiple malignancies. tumour cell lines Inthepresentstudyweemployedagenome-wide We used COBRA digest to ascertain the methylation approach to identify methylated genes in breast cancer levels across a panel of 9 breast cancer cell lines (includ- and further investigated these genes in other common ing the 5 lines used for MIRA) in CpG island regions epithelial cancers. For the high throughput genome- upstream of the transcription start site. We confirmed wide DNA methylation approach we utilized a very sen- frequent methylation (>30%) for 16 loci in breast cancer sitive assay recently developed in our laboratory (Gerd cell lines. These loci were unmethylated in DNA from Pfeifer lab). The methylated-CpG island recovery assay normal/control breast. Sixteen loci either showed low or (MIRA) is based on the high affinity of the MBD2/ no methylation in the panel of breast cancer cell lines MBD3L1 complex for methylated DNA and allows one or were equally methylated in normal control breast to detect cell type-dependent differences in DNA DNA in the region analysed by our COBRA primers methylation when used in combination with CpG island and were removed from further analysis (Figure 1). The arrays [7,8]. remaining 16 positive genes demonstrating frequent methylation in breast cancer cell lines were analysed Results further by COBRA digest in a panel of primary breast Genome-wide approach identifies methylated genes in tumours(n=40).Nine(CIDE-A,COMP,DBC1,EMI- breast cancer LIN2, EPSTI1, FBLN2, SALL1, SESN3, SIM2) of these We used the MIRA assay in combination with genome- genes (56%) demonstrated frequent methylation in pri- wide CpG island arrays containing 27,800 loci to identify mary breast tumours (frequency ranging from 26-63%) methylated CpG islands in 5 breast cancer cell lines (Figure 1, 2, 3, 4, 5, 6) (HCC1806, HCC1419, HCC1143, HCC1937, HCC1395) relative to normal human mammary epithelial cells Expression analysis in breast tumour cell lines and (NHMEC) [7,8]. A primary selection based on probes normal breast showing > 5 fold enrichment of the methylated fraction The above nine frequently methylated genes were shown in breast cancer cell lines versus NHMEC cell line DNA to be expressed in normal breast tissue (Figure 2, 3, 4, 5, across 3 or more cell lines or a more stringent selection 6). In order to determine the role of methylation in gene with probes scoring greater than 10 in 4 or more cell silencing, we treated breast cancer cell lines with the lines yielded a large number of loci showing methylation demethylating agent 5-aza-dC. Eight (CIDE-A, COMP, across breast cancer cell lines (see additional 1). These DBC1, EMILIN2, EPSTI1, FBLN2, SALL1, SIM2)ofthe included genes/loci previously reported to be methylated above nine genes showed re-expression after treatment in breast cancer (for example SIM1, PAX6, DLX4, of the methylated cell lines with 5aza-dC (Figure 2, 3, 4, RUNX3). In order to reduce the list to manageable 5, 6). Hence methylation suppressed gene expression, numbers we carried out bioinformatic analyses to gather whilst SESN3 showed no change in expression before information on the expression of target genes in breast and after treatment in both methylated and unmethy- tissue, confirmation of the presence of a CpG island lated cell lines. SESN3 was therefore not considered for within the likely promoter region of target genes and further analysis. functional annotation to determine likely roles in tumourigenesis, see materials and methods for more Methylation analysis in paired normal/ information. This led to a selection of 32 novel genes tumour breast cases for further analysis (Figure 1, see additional file 2) in a To determine if methylation of the eight remaining stepwise fashion including the following stages: genes was cancer-specific (i.e. tumour acquired), we ana- lysed an independent set of paired
Load more

Recommended publications
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: a Review of Novel Insights
    International Journal of Molecular Sciences Review Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights Paola Berenice Mass Sanchez, Marinela Krizanac, Ralf Weiskirchen * and Anastasia Asimakopoulos * Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany; [email protected] (P.B.M.S.); [email protected] (M.K.) * Correspondence: [email protected] (R.W.); [email protected] (A.A.) Abstract: Consumption of high-calorie foods, such as diets rich in fats, is an important factor leading to the development of steatohepatitis. Several studies have suggested how lipid accumulation creates a lipotoxic microenvironment for cells, leading cells to deregulate their transcriptional and transla- tional activity. This deregulation induces the development of liver diseases such as non-alcoholic fatty liver disease (NAFLD) and subsequently also the appearance of hepatocellular carcinoma (HCC) which is one of the deadliest types of cancers worldwide. Understanding its pathology and studying new biomarkers with better specificity in predicting disease prognosis can help in the personalized treatment of the disease. In this setting, understanding the link between NAFLD and HCC progression, the differentiation of each stage in between as well as the mechanisms underlying this process, are vital for development of new treatments and in exploring new therapeutic targets. Citation: Mass Sanchez, P.B.; Perilipins are a family of five closely related proteins expressed on the surface of lipid droplets (LD) in Krizanac, M.; Weiskirchen, R.; several tissues acting in several pathways involved in lipid metabolism.
    [Show full text]
  • Identification of 5 Novel Genes Methylated in Breast and Other Epithelial Cancers
    Hill et al. Molecular Cancer 2010, 9:51 http://www.molecular-cancer.com/content/9/1/51 RESEARCH Open Access Identification of 5 novel genes methylated in breast and other epithelial cancers Victoria K Hill1, Luke B Hesson1,2, Temuujin Dansranjavin3, Ashraf Dallol1, Ivan Bieche4, Sophie Vacher4, Stella Tommasi5, Timothy Dobbins2, Dean Gentle1, David Euhus6, Cheryl Lewis6, Reinhard Dammann3, Robyn L Ward2, John Minna7, Eammon R Maher1, Gerd P Pfeifer5, Farida Latif1* Abstract Background: There are several high throughput approaches to identify methylated genes in cancer. We utilized one such recently developed approach, MIRA (methylated-CpG island recovery assay) combined with CpG island arrays to identify novel genes that are epigenetically inactivated in breast cancer. Results: Using this approach we identified numerous CpG islands that demonstrated aberrant DNA methylation in breast cancer cell lines. Using a combination of COBRA and sequencing of bisulphite modified DNA, we confirmed 5 novel genes frequently methylated in breast tumours; EMILIN2, SALL1, DBC1, FBLN2 and CIDE-A. Methylation frequencies ranged from between 25% and 63% in primary breast tumours, whilst matched normal breast tissue DNA was either unmethylated or demonstrated a much lower frequency of methylation compared to malignant breast tissue DNA. Furthermore expression of the above 5 genes was shown to be restored following treatment with a demethylating agent in methylated breast cancer cell lines. We have expanded this analysis across three other common epithelial cancers (lung, colorectal, prostate). We demonstrate that the above genes show varying levels of methylation in these cancers. Lastly and most importantly methylation of EMILIN2 was associated with poorer clinical outcome in breast cancer and was strongly associated with estrogen receptor as well as progesterone receptor positive breast cancers.
    [Show full text]
  • Transdifferentiation of Human Mesenchymal Stem Cells
    Transdifferentiation of Human Mesenchymal Stem Cells Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Tatjana Schilling aus San Miguel de Tucuman, Argentinien Würzburg, 2007 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Martin J. Müller Gutachter: PD Dr. Norbert Schütze Gutachter: Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die von mir angegebenen Hilfsmittel und Quellen verwendet habe. Des Weiteren erkläre ich, dass diese Arbeit weder in gleicher noch in ähnlicher Form in einem Prüfungsverfahren vorgelegen hat und ich noch keinen Promotionsversuch unternommen habe. Gerbrunn, 4. Mai 2007 Tatjana Schilling Table of contents i Table of contents 1 Summary ........................................................................................................................ 1 1.1 Summary.................................................................................................................... 1 1.2 Zusammenfassung..................................................................................................... 2 2 Introduction.................................................................................................................... 4 2.1 Osteoporosis and the fatty degeneration of the bone marrow..................................... 4 2.2 Adipose and bone
    [Show full text]
  • DBC1 Antibody A
    C 0 2 - t DBC1 Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 3 9 Web: [email protected] 6 www.cellsignal.com 5 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB, IP, IF-IC H M R Mk Endogenous 130 Rabbit Q8N163 57805 Product Usage Information 1. Hamaguchi, M. et al. (2002) Proc Natl Acad Sci USA 99, 13647-52. 2. Trauernicht, A.M. et al. (2007) Mol Endocrinol 21, 1526-36. Application Dilution 3. Zhao, W. et al. (2008) Nature 451, 587-90. 4. Li, Z. et al. (2009) J Biol Chem 284, 10361-6. Western Blotting 1:1000 5. Sundararajan, R. et al. (2005) Oncogene 24, 4908-20. Immunoprecipitation 1:50 Immunofluorescence (Immunocytochemistry) 1:100 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity DBC1 Antibody detects endogenous levels of total DBC1 protein. Species Reactivity: Human, Mouse, Rat, Monkey Species predicted to react based on 100% sequence homology: Horse Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human DBC1 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Deleted in breast cancer gene 1 protein (DBC1) was originally identified by its localization to a region of chromosome 8p21 that is homozygously deleted in breast cancer (1).
    [Show full text]
  • Dephosphorylation of DBC1 by Protein Phosphatase 4 Is Important for P53-Mediated Cellular Functions
    Dephosphorylation of DBC1 by Protein Phosphatase 4 Is Important for p53-Mediated Cellular Functions The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Lee, Jihye, Guillaume Adelmant, Jarrod A. Marto, and Dong-Hyun Lee. 2015. “Dephosphorylation of DBC1 by Protein Phosphatase 4 Is Important for p53-Mediated Cellular Functions.” Molecules and Cells 38 (8): 697-704. doi:10.14348/molcells.2015.0066. http:// dx.doi.org/10.14348/molcells.2015.0066. Published Version doi:10.14348/molcells.2015.0066 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:22857022 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Mol. Cells 2015; 38(8): 697-704 http://dx.doi.org/10.14348/molcells.2015.0066 Molecules and Cells http://molcells.org Established in 1990 Dephosphorylation of DBC1 by Protein Phosphatase 4 Is Important for p53-Mediated Cellular Functions Jihye Lee, Guillaume Adelmant1, Jarrod A. Marto1, and Dong-Hyun Lee* Deleted in breast cancer-1 (DBC1) contributes to the regu- ATM/ATR kinases (Zannini et al., 2012) and it plays a critical lation of cell survival and apoptosis. Recent studies role in maintaining genomic stability and cellular integrity follow- demonstrated that DBC is phosphorylated at Thr454 by ing genotoxic stress (Kim et al., 2008; 2009a; Magni et al., 2014; ATM/ATR kinases in response to DNA damage, which is a Park et al., 2014; Zannini et al., 2012; Zheng et al., 2013).
    [Show full text]
  • Regulate Cancer?
    NIH Public Access Author Manuscript Cellscience. Author manuscript; available in PMC 2009 September 10. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Cellscience. 2008 April 1; 4(4): 50±56. Can Sir(2) regulate cancer? Pratibha V. Nerurkar1 and Vivek R. Nerurkar2 1 Laboratory of Metabolic Disorders and Alternative Medicine, Dept. of Molecular Biosciences and Bioengineering (MBBE), CTAHR, , University of Hawaii, Honolulu 2 Retrovirology Research Laboratory, Dept. of Tropical Medicine, Medical Microbiology & Pharmacology, Asia-Pacific Institute of Tropical Medicine and Infectious Diseases, John A. Burns School of Medicine, University of Hawaii, Honolulu Abstract Sirtuin activators, including small molecules such as polyphenols and resveratrol, are much desired due to their potential to ameliorate metabolic disorder and delay or prevent aging. In contrast, recent studies demonstrate that targeted silencing of sirtuin 1 (SIRT1) expression or activity by the deleted in breast cancer 1 (DBC1) may be beneficial by promoting p53-induced apoptosis in cancer cells, and by sensitizing cancerous cells to radiation therapy. Negative SIRT1 regulation also alleviates gene-repression associated with fragile X mental retardation syndrome. The targeted activation or inhibition of SIRT1 activity therefore emerges as a critical point of regulation in disease pathogenesis. Sirtuin 1 (SIRT1), mammalian homologue of the silencing information regulator 2 (Sir2) yeast gene, is a class III nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase that is conserved across species and plays an important role in extending lifespan [1]. Located within the nucleus, SIRT1 regulates cell survival by modulating cellular stress, metabolic pathways and apoptosis. Although the numerous targets and functions of SIRT1 are constantly being unraveled (as summarized in Figure 1 and reviewed in [2–6]), cell survival was initially demonstrated to involve the SIRT-associated deacetylation of tumor suppressor gene, p53 [7–9].
    [Show full text]
  • Negative Regulation of G1/S Transition by the Candidate Bladder Tumour Suppressor Gene DBCCR1
    Oncogene (2001) 20, 2956 ± 2964 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1 Hiroyuki Nishiyama1, Jason H Gill1, Eva Pitt1, Wendy Kennedy1 and Margaret A Knowles*,1 1ICRF Clinical Centre, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK Deletion of all or part of chromosome 9q is the most and/or 9q and one of these genes might represent a common genetic alteration in all stages and grades of `gatekeeper' for urothelial cells (Kinzler and Vogelstein, bladder cancer. DBCCR1 (deleted in bladder cancer 1996). Detailed LOH studies of chromosome 9q in chromosome region candidate 1) maps to the chromosome TCC have indicated that there are several candidate region 9q32-33, a candidate tumour suppressor locus for tumour suppressor loci (Cairns et al., 1993; Dalbagni et bladder cancer. Although no mutations of DBCCR1 have al., 1993; Olumi et al., 1990; Simoneau et al., 1999), been detected in bladder tumours, expression of DBCCR1 one of which is at 9q32-33 (Habuchi et al., 1995, 1997; is silenced by promoter hypermethylation in 50% of Nishiyama et al., 1999b). The putative tumour bladder cancer cell lines analysed. Here we sought to suppressor gene in this region has been designated provide functional evidence to authenticate DBCCR1 as a DBC1 (deleted in bladder cancer 1). Using YAC and tumour suppressor using gene-transfer methods. Exogen- PAC contigs spanning the DBC1 region, we identi®ed a ous expression of DBCCR1 protein or an HA epitope- candidate tumour suppressor gene, DBCCR1 (deleted tagged fusion protein, HA-DBCCR1 in NIH3T3 cells and in bladder cancer chromosomal region candidate 1) human bladder tumour cell lines resulted in suppression of (Habuchi et al., 1998; Nishiyama et al., 1999a).
    [Show full text]
  • AM 112.Indd 3 04.05.12 11:31 the Genes Found to Be Associated with SZ Using Computer Ance of Researched Population, and Linkage Disequilibrium Gene Databases (28, 46)
    REVIEW ARTICLE GENOME ‑WIDE ASSOCIATION STUDIES IN SCHIZOPHRENIA, AND POTENTIAL ETIOLOGICAL AND FUNCTIONAL IMPLICATIONS OF THEIR RESULTS Ladislav Hosák1,2, Petr Šilhan2, Jiřina Hosáková2 Charles University in Prague, Faculty of Medicine in Hradec Králové, and University Hospital Hradec Králové, Czech Repub‑ lic: Department of Psychiatry1; University of Ostrava, Faculty of Medicine, and University Hospital Ostrava, Czech Republic: Department of Clinical Studies and Department of Psychiatry2 Summary: Background: Despite the fact that the genetic basis of schizophrenia has been intensively studied for more than two decades, our contemporary knowledge in this field is rather fractional, and a substantial part of it is still missing. The aim of this review article is to sum up the data coming from genome ‑wide association genetic studies in schizophrenia, and indicate prospective directions of further scientific endeavour. Methods: We searched the National Human Genome Research Institute’s Catalog of genome‑wide association studies for schizophrenia to identify all papers related to this topic. In consequence, we looked up the possible relevancy of these findings for etiology and pathogenesis of schizophrenia using the computer gene and PubMed databases. Results: Eighteen genome‑wide association studies in schizophrenia have been published till now, referring to fifty‑seven genes supposedly involved into schizophrenia’s etiopathogenesis. Most of these genes are related to neurodevelopment, neuroendocrinology, and immunology. Conclusions: It
    [Show full text]
  • The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression*□S
    crossmark Research © 2016 by The American Society for Biochemistry and Molecular Biology, Inc. This paper is available on line at http://www.mcponline.org The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression*□S Sophie S. B. Gigue`re‡¶, Amanda J. Guise‡¶, Pierre M. Jean Beltran‡¶, Preeti M. Joshi‡¶, Todd M. Greco‡, Olivia L. Quach‡, Jeffery Kong‡, and Ileana M. Cristea‡§ Deleted in breast cancer 1 (DBC1) has emerged as an nance of the circadian molecular clock. Furthermore, the important regulator of multiple cellular processes, rang- identified interactions provide a valuable resource for the ing from gene expression to cell cycle progression. DBC1 exploration of pathways involved in DBC1-associated has been linked to tumorigenesis both as an inhibitor of tumorigenesis. Molecular & Cellular Proteomics 15: histone deacetylases, HDAC3 and sirtuin 1, and as a tran- 10.1074/mcp.M115.054619, 791–809, 2016. scriptional cofactor for nuclear hormone receptors. How- ever, despite mounting interest in DBC1, relatively little is known about the range of its interacting partners and the Deleted in breast cancer 1 (DBC1)1 was first identified by scope of its functions. Here, we carried out a functional cloning a human chromosomal region observed to be ho- proteomics-based investigation of DBC1 interactions in mozygously deleted in multiple breast cancers (1). Having two relevant cell types, T cells and kidney cells. Micros- gained prominence as an important regulator of gene expres- copy, molecular biology, biochemistry, and mass spec- sion, DBC1 is now known to have additional functions in trometry studies allowed us to assess DBC1 mRNA and chromatin remodeling, transcriptional regulation, and modu- protein levels, localization, phosphorylation status, and protein interaction networks.
    [Show full text]
  • Nuclear Perilipin 5 Integrates Lipid Droplet Lipolysis with PGC-1&Alpha
    ARTICLE Received 28 Sep 2015 | Accepted 27 Jul 2016 | Published 24 Aug 2016 DOI: 10.1038/ncomms12723 OPEN Nuclear Perilipin 5 integrates lipid droplet lipolysis with PGC-1a/SIRT1-dependent transcriptional regulation of mitochondrial function Violeta I. Gallardo-Montejano1, Geetu Saxena2, Christine M. Kusminski3, Chaofeng Yang1, John L. McAfee1, Lisa Hahner1, Kathleen Hoch2, William Dubinsky2, Vihang A. Narkar2 & Perry E. Bickel1 Dysfunctional cellular lipid metabolism contributes to common chronic human diseases, including type 2 diabetes, obesity, fatty liver disease and diabetic cardiomyopathy. How cells balance lipid storage and mitochondrial oxidative capacity is poorly understood. Here we identify the lipid droplet protein Perilipin 5 as a catecholamine-triggered interaction partner of PGC-1a. We report that during catecholamine-stimulated lipolysis, Perilipin 5 is phosphory- lated by protein kinase A and forms transcriptional complexes with PGC-1a and SIRT1 in the nucleus. Perilipin 5 promotes PGC-1a co-activator function by disinhibiting SIRT1 deacetylase activity. We show by gain-and-loss of function studies in cells that nuclear Perilipin 5 promotes transcription of genes that mediate mitochondrial biogenesis and oxidative function. We propose that Perilipin 5 is an important molecular link that couples the coordinated catecholamine activation of the PKA pathway and of lipid droplet lipolysis with transcriptional regulation to promote efficient fatty acid catabolism and prevent mitochondrial dysfunction. 1 Division of Endocrinology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. 2 Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for The Prevention Of Human Diseases, UT Health, Houston, Texas 77030, USA.
    [Show full text]
  • LKB1 Negatively Regulates AKT1 Signaling Via DBC1 and TRB3
    bioRxiv preprint doi: https://doi.org/10.1101/691402; this version posted July 3, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. LKB1 negatively regulates AKT1 signaling via DBC1 and TRB3 Zarka Sarwar1, Sameer Bhat1, Qaaifah Gillani1, Irfana Reshi1, Misbah Un Nisa1, Guillaume Adelmant2, Jarrod Marto2, Shaida Andrabi1 1 Department of Biochemistry, University of Kashmir, Srinagar, India-190006. Blais Proteomics Centre, Dana Farber Cancer Institute, Harvard University, Boston, USA. Correspondence: Shaida Andrabi; Department of Biochemistry, University of Kashmir, Hazratbal, Srinagar, 190006, India. [email protected]; Tel. (+91) 962-220-9997 Abstract DBC1 plays a critical role in various cellular functions notably cell proliferation, transcription, histone modification and adipogenesis. Current reports about the role of DBC1 in tumorigenesis are paradoxical and designate DBC1 both as a tumor suppressor or an oncogene. Here, using small T antigen of polyoma virus (PyST) as a tool, we have delineated a signaling mechanism that connects LKB1 to AKT1 via DBC1. We report that PyST associates with DBC1 and leads to its down- regulation. Our results also show that PyST expression promotes LKB1 activation which in turn leads to in the downregulation of DBC1 protein. Absence of DBC1 results in transcriptional upregulation and consequently enhanced protein levels of TRB3. TRB3 sequesters AKT1, and consequently the phosphorylation and activity of AKT1 is compromised. This ultimately results in inactivation of pro- survival pathways triggered via AKT1 signaling.
    [Show full text]